{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,8,11]],"date-time":"2022-08-11T00:12:04Z","timestamp":1660176724301},"reference-count":31,"publisher":"Oxford University Press (OUP)","issue":"48","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2017,12,21]]},"DOI":"10.1093\/eurheartj\/ehx729","type":"journal-article","created":{"date-parts":[[2017,12,21]],"date-time":"2017-12-21T10:13:37Z","timestamp":1513851217000},"page":"3541-3544","source":"Crossref","is-referenced-by-count":1,"title":["Frontiers of lipid research: cholesterol variability, HDL biogenesis, genetics of myalgia, and lipoprotein(a)"],"prefix":"10.1093","volume":"38","author":[{"given":"Thomas F","family":"L\u00fcscher","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2017,12,21]]},"reference":[{"key":"key\n\t\t\t\t20171221050448_ehx729-B1","first-page":"810","article-title":"Vortrag \u00fcber den atheromat\u00f6sen Process der Arterien","volume":"51","year":"1856","journal-title":"Wien Med Wochenschr"},{"key":"key\n\t\t\t\t20171221050448_ehx729-B2","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1007\/BF01929776","article-title":"Die Lehre von der chronischen Endoarteriitis","volume":"77","year":"1879","journal-title":"Virchows Arch"},{"key":"key\n\t\t\t\t20171221050448_ehx729-B3","first-page":"306","article-title":"Uber die Atherosklerose der Aorta beim Kaninchen und uber deren Entstehungsbedingungen","volume":"59","year":"1914","journal-title":"Beitr Path Anat Allg Pathol"},{"key":"key\n\t\t\t\t20171221050448_ehx729-B4","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/BF01891331","article-title":"Zur \u00c4tiologie der Atherosklerose","volume":"249","year":"1924","journal-title":"Virchows Arch"},{"key":"key\n\t\t\t\t20171221050448_ehx729-B5","first-page":"178","volume-title":"Arteriosclerosis (Dallas, Tex)","year":"1983"},{"key":"key\n\t\t\t\t20171221050448_ehx729-B6","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/1047-2797(92)90033-M","article-title":"Lipids and risk of coronary heart disease. The Framingham Study","volume":"2","year":"1992","journal-title":"Ann Epidemiol"},{"key":"key\n\t\t\t\t20171221050448_ehx729-B7","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S0022-2275(20)41379-3","article-title":"The discovery and development of HMG-CoA reductase inhibitors","volume":"33","year":"1992","journal-title":"J Lipid Res"},{"key":"key\n\t\t\t\t20171221050448_ehx729-B8","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","year":"1994","journal-title":"Lancet"},{"key":"key\n\t\t\t\t20171221050448_ehx729-B9","article-title":"Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration","year":"2017","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20171221050448_ehx729-B10","doi-asserted-by":"crossref","first-page":"3560","DOI":"10.1093\/eurheartj\/ehx585","article-title":"Cholesterol variability and the risk of mortality, myocardial infarction, and stroke: a nationwide population-based study","volume":"38","year":"2017","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20171221050448_ehx729-B11","doi-asserted-by":"crossref","first-page":"3567","DOI":"10.1093\/eurheartj\/ehx656","article-title":"Cholesterol variability: a marker for increased risk or a risk factor?","volume":"38","year":"2017","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20171221050448_ehx729-B12","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1093\/eurheartj\/ehv043","article-title":"Statin-associated muscle symptoms: impact on statin therapy: European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management","volume":"36","year":"2015","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20171221050448_ehx729-B13","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1093\/eurheartj\/ehx467","article-title":"A common missense variant of LILRB5 is associated with statin intolerance and myalgia","volume":"38","year":"2017","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20171221050448_ehx729-B14","doi-asserted-by":"crossref","first-page":"3576","DOI":"10.1093\/eurheartj\/ehx586","article-title":"Leucocyte immunoglobulin-like receptor subfamily-B5 (LILRB5) genetic variation and statin-associated muscle symptoms: another piece in a puzzling puzzle","volume":"38","year":"2017","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20171221050448_ehx729-B15","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","article-title":"Effects of torcetrapib in patients at high risk for coronary events","volume":"357","year":"2007","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171221050448_ehx729-B16","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.1056\/NEJMoa1206797","article-title":"Effects of dalcetrapib in patients with a recent acute coronary syndrome","volume":"367","year":"2012","journal-title":"N Engl J Med"},{"key":"key\n\t\t\t\t20171221050448_ehx729-B17","doi-asserted-by":"crossref","first-page":"3277","DOI":"10.1093\/eurheartj\/ehu171","article-title":"Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial","volume":"35","year":"2014","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20171221050448_ehx729-B18","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1161\/CIRCRESAHA.114.300935","article-title":"High-density lipoprotein: vascular protective effects, dysfunction, and potential as therapeutic target","volume":"114","year":"2014","journal-title":"Circ Res"},{"key":"key\n\t\t\t\t20171221050448_ehx729-B19","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1093\/eurheartj\/ehx118","article-title":"Symmetric dimethylarginine, high-density lipoproteins and cardiovascular disease","volume":"38","year":"2017","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20171221050448_ehx729-B20","doi-asserted-by":"crossref","first-page":"2478","DOI":"10.1093\/eurheartj\/ehx163","article-title":"Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies","volume":"38","year":"2017","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20171221050448_ehx729-B21","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1093\/eurheartj\/ehu264","article-title":"HDL cholesterol subclasses, myocardial infarction, and mortality in secondary prevention: the Lipoprotein Investigators Collaborative","volume":"36","year":"2015","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20171221050448_ehx729-B22","doi-asserted-by":"crossref","first-page":"3579","DOI":"10.1093\/eurheartj\/ehx315","article-title":"TRAK2, a novel regulator of ABCA1 expression, cholesterol efflux, and HDL biogenesis","volume":"38","year":"2017","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20171221050448_ehx729-B23","doi-asserted-by":"crossref","first-page":"3588","DOI":"10.1093\/eurheartj\/ehx506","article-title":"Making sense of a seemingly odd connection","volume":"38","year":"2017","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20171221050448_ehx729-B24","doi-asserted-by":"crossref","first-page":"3590","DOI":"10.1093\/eurheartj\/ehx517","article-title":"CD27 co-stimulation increases the abundance of regulatory T cells and reduces atherosclerosis in hyperlipidaemic mice","volume":"38","year":"2017","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20171221050448_ehx729-B25","doi-asserted-by":"crossref","first-page":"3600","DOI":"10.1093\/eurheartj\/ehx630","article-title":"Protective role of the co-stimulator CD27 receptor and regulatory T cells in early atherogenesis","volume":"38","year":"2017","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20171221050448_ehx729-B26","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1093\/eurheartj\/ehx033","article-title":"Lipoprotein(a): the revenant","volume":"38","year":"2017","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20171221050448_ehx729-B27","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.1093\/eurheartj\/ehx546","article-title":"Depicting new pharmacological strategies for familial hypercholesterolaemia involving lipoprotein (a)","volume":"38","year":"2017","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20171221050448_ehx729-B28","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1093\/eurheartj\/ehv563","article-title":"The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis","volume":"37","year":"2016","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20171221050448_ehx729-B29","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1093\/eurheartj\/ehv707","article-title":"Safety and efficacy of LY3015014, a monoclonal antibody to proprotein convertase subtilisin\/kexin type 9 (PCSK9): a randomized, placebo-controlled Phase 2 study","volume":"37","year":"2016","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20171221050448_ehx729-B30","first-page":"2966","article-title":"Lipoprotein(a): another emergent target for PCSK9 inhibitors?","volume":"37","year":"2016","journal-title":"Eur Heart J"},{"key":"key\n\t\t\t\t20171221050448_ehx729-B31","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.2174\/1381612823666170125160108","article-title":"Apolipoprotein(a) antisense oligonucleotides: a new treatment option for lowering elevated lipoprotein(a)?","volume":"23","year":"2017","journal-title":"Curr Pharm Des"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/eurheartj\/article-pdf\/38\/48\/3541\/22964550\/ehx729.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,10]],"date-time":"2022-08-10T23:46:23Z","timestamp":1660175183000},"score":1,"resource":{"primary":{"URL":"http:\/\/academic.oup.com\/eurheartj\/article\/38\/48\/3541\/4767716"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,21]]},"references-count":31,"journal-issue":{"issue":"48","published-online":{"date-parts":[[2017,12,21]]},"published-print":{"date-parts":[[2017,12,21]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehx729","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2017,12,21]]},"published":{"date-parts":[[2017,12,21]]}}}